-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Jefferies Financial Group Analysts Increase Earnings Estimates for Calliditas Therapeutics AB (Publ) (NASDAQ:CALT)
Jefferies Financial Group Analysts Increase Earnings Estimates for Calliditas Therapeutics AB (Publ) (NASDAQ:CALT)
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) – Research analysts at Jefferies Financial Group boosted their FY2023 earnings estimates for Calliditas Therapeutics AB (publ) in a research report issued to clients and investors on Friday, August 19th. Jefferies Financial Group analyst M. Raycroft now anticipates that the company will earn $4.11 per share for the year, up from their previous estimate of $3.91. The consensus estimate for Calliditas Therapeutics AB (publ)'s current full-year earnings is ($2.81) per share. Jefferies Financial Group also issued estimates for Calliditas Therapeutics AB (publ)'s FY2024 earnings at $6.74 EPS, FY2025 earnings at $8.69 EPS and FY2026 earnings at $11.10 EPS.
Get Calliditas Therapeutics AB (publ) alerts:Several other research firms have also commented on CALT. Pareto Securities started coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 2nd. They set a "buy" rating for the company. Kepler Capital Markets started coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 16th. They set a "buy" rating for the company. Finally, TheStreet upgraded shares of Calliditas Therapeutics AB (publ) from a "d+" rating to a "c-" rating in a research report on Thursday, August 4th.
Calliditas Therapeutics AB (publ) Stock Down 10.4 %
Calliditas Therapeutics AB (publ) stock opened at $16.13 on Monday. The company has a 50-day simple moving average of $18.77 and a 200-day simple moving average of $18.27. The firm has a market capitalization of $429.46 million, a P/E ratio of -6.48 and a beta of 1.60. The company has a debt-to-equity ratio of 0.25, a quick ratio of 5.36 and a current ratio of 5.37. Calliditas Therapeutics AB has a one year low of $12.55 and a one year high of $32.24.Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)
A hedge fund recently raised its stake in Calliditas Therapeutics AB (publ) stock. Ironwood Investment Management LLC raised its holdings in Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) by 5.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,762 shares of the company's stock after acquiring an additional 1,495 shares during the quarter. Ironwood Investment Management LLC owned 0.11% of Calliditas Therapeutics AB (publ) worth $551,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 25.10% of the company's stock.
About Calliditas Therapeutics AB (publ)
(Get Rating)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Read More
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Apple's Stock Could Be On The Verge Of Another 30% Rally
- Near-Term Headwinds Present An Opportunity In Ross Stores
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) – Research analysts at Jefferies Financial Group boosted their FY2023 earnings estimates for Calliditas Therapeutics AB (publ) in a research report issued to clients and investors on Friday, August 19th. Jefferies Financial Group analyst M. Raycroft now anticipates that the company will earn $4.11 per share for the year, up from their previous estimate of $3.91. The consensus estimate for Calliditas Therapeutics AB (publ)'s current full-year earnings is ($2.81) per share. Jefferies Financial Group also issued estimates for Calliditas Therapeutics AB (publ)'s FY2024 earnings at $6.74 EPS, FY2025 earnings at $8.69 EPS and FY2026 earnings at $11.10 EPS.
卡里迪塔斯治療公司(Publ)(納斯達克代碼：CALT-GET Rating)-傑富瑞金融集團的研究分析師在8月19日(星期五)發佈給客户和投資者的一份研究報告中上調了他們對卡里迪塔斯治療公司(Publ)2023財年的收益預期。傑富瑞金融集團(Jefferies Financial Group)分析師雷克羅夫特(M.Raycroft)現在預計，該公司今年的每股收益為4.11美元，高於此前預測的3.91美元。對Calliditas Treateutics AB(Publ)目前全年收益的普遍預期為每股2.81美元。Jefferies Financial Group還發布了對Calliditas Treateutics AB(Publ)2024財年每股收益6.74美元、2025財年每股收益8.69美元和2026財年每股收益11.10美元的預期。
Several other research firms have also commented on CALT. Pareto Securities started coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 2nd. They set a "buy" rating for the company. Kepler Capital Markets started coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 16th. They set a "buy" rating for the company. Finally, TheStreet upgraded shares of Calliditas Therapeutics AB (publ) from a "d+" rating to a "c-" rating in a research report on Thursday, August 4th.
其他幾家研究公司也對CALT發表了評論。帕累託證券於6月2日星期四在一份研究報告中開始報道Calliditas Treateutics AB(Publ)的股票。他們為該公司設定了“買入”評級。開普勒資本市場於6月16日星期四在一份研究報告中開始報道Calliditas Treateutics AB(Publ)的股票。他們為該公司設定了“買入”評級。最後，在8月4日星期四的一份研究報告中，華爾街將Calliditas治療公司(Publ)的股票評級從“d+”上調至“c-”。
Calliditas Therapeutics AB (publ) Stock Down 10.4 %
Calliditas Treateutics AB(Publ)股價下跌10.4%
Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)
機構投資者買入Calliditas Treateutics AB(Publ)
A hedge fund recently raised its stake in Calliditas Therapeutics AB (publ) stock. Ironwood Investment Management LLC raised its holdings in Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) by 5.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,762 shares of the company's stock after acquiring an additional 1,495 shares during the quarter. Ironwood Investment Management LLC owned 0.11% of Calliditas Therapeutics AB (publ) worth $551,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 25.10% of the company's stock.
一家對衝基金最近增持了Calliditas Treateutics AB(Publ)的股票。根據Ironwood Investment Management LLC提交給美國證券交易委員會的最新13F文件，該公司在第一季度將其在Calliditas Treateutics AB(Publ)(納斯達克代碼：CALT-GET評級)的持股增加了5.5%。該基金在本季度增持了1,495股後，持有該公司28,762股股票。截至最近提交給美國證券交易委員會的文件，Ironwood Investment Management LLC擁有Calliditas Treateutics AB(Publ)0.11%的股份，價值55.1萬美元。機構投資者和對衝基金持有該公司25.10%的股票。
About Calliditas Therapeutics AB (publ)
關於Calliditas Treateutics AB(Publ)
(Get Rating)
(獲取評級)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Calliditas Treateutics AB(Publ)是一家臨牀階段的生物製藥公司，專注於識別、開發和商業化用於孤兒適應症治療的藥物產品，最初的重點是腎臟和肝臟疾病。它提供Nefecon，一種口服布地奈德製劑，是一種治療自身免疫性腎病免疫球蛋白A腎病的免疫抑制劑。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Apple's Stock Could Be On The Verge Of Another 30% Rally
- Near-Term Headwinds Present An Opportunity In Ross Stores
- 免費獲取StockNews.com關於Calliditas Treateutics AB(Publ)(CALT)的研究報告
- 2家電動汽車供應商在提出意見後上漲
- 應用材料公司業績顯示半導體市場放緩
- MarketBeat：回顧中的一週8/15-8/19
- 蘋果股價可能再次上漲30%
- 近期逆風為Ross Stores帶來機遇
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
接受Calliditas Treateutics AB(Publ)Daily的新聞和評級-在下面輸入您的電子郵件地址，以通過MarketBeat.com的免費每日電子郵件時事通訊接收對Calliditas Treateutics AB(Publ)和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧